#HVO hVIVO PLC – £6m Influenza HCT contract signed May 7, 2026 – Posted in: hVIVO (HVO)

London, UK – 7 May 2026, hVIVO plc (AIM: HVO), a purpose-built, full-service international clinical development partner and the world leader in human challenge trials, announces that it has signed a £6 million Clinical Trial Agreement (“CTA”) to conduct a human challenge (HCT) trial on behalf of a clinical-stage biopharmaceutical company developing novel therapies for respiratory viral diseases. The trial will evaluate the monoclonal antibody using the hVIVO Influenza Human Challenge Study Model. This will be a randomised, double-blinded placebo-controlled trial…

#HVO hVIVO PLC – HCT contract signed with ILiAD Biotechnologies April 22, 2026 – Posted in: hVIVO (HVO)

· World’s first pivotal Phase III human challenge trial (“HCT”) in Bordetella pertussis (the bacteria that causes whooping cough) for ILiAD Biotechnologies vaccine candidate, BPZE1 · hVIVO’s largest HCT to date, with over 500 participants anticipated, with revenue recognition expected from H1 2026 · Trial expected to be hVIVO’s largest value HCT to date; making a strong contribution to near and mid‑term revenues with the majority expected to be recognised during 2026 and 2027 London, UK – 22 April 2026, hVIVO plc (AIM: HVO), a purpose-built,…

#HVO hVIVO PLC – Positive results from flu human challenge study October 5, 2023 – Posted in: Blog, hVIVO (HVO)

hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, notes the announcement by Pneumagen, a clinical-stage biotech company, reporting successful clinical proof of concept for its broad-spectrum antiviral candidate Neumifil, demonstrated from a Phase 2a influenza human challenge study conducted by hVIVO. The randomised, double-blind, placebo-controlled study enrolled 104 healthy adult volunteers, recruited through the FluCamp platform, and evaluated two dose regimens…

#HVO hVIVO PLC – Plans for a new larger state-of-the-art facility August 29, 2023 – Posted in: Blog, hVIVO (HVO)

· Capacity increase to 50 quarantine beds with optionality to expand to 70 · Expansion of laboratory services to include cutting edge labs · Largely funded by multiple hVIVO clients hVIVO plc (AIM & Euronext: HVO), the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its plans for a new consolidated facility at the fast-growing life sciences hub in Canary Wharf, London. The expansion, largely funded by hVIVO…

Open Orphan #ORPH – £7.2m RSV human challenge study contract June 14, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £7.2m contract with an existing top 5 global pharmaceutical company to test its orally administered antiviral product, using hVIVO’s respiratory syncytial virus (“RSV”) Human Challenge Study Model. The Phase 2a double-blinded placebo-controlled human challenge study will take…

Open Orphan #ORPH – Final results Reveal Record revenues and EBITDA-profitability accompanied by significant operational progress June 7, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces its audited final results for the 12 months ended 31 December 2021. Financial highlights · Record revenues of £39.0m (2020: £22.2m) achieved representing 76% growth · £9m improvement in EBITDA generating £2.9m (2020: £(6.1)m) · Cash and cash equivalents as at 31 December 2021 of £15.7m…

Open Orphan #ORPH – £7.3m Influenza human challenge study contract win May 18, 2022 – Posted in: Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, announces that hVIVO, a subsidiary of Open Orphan, has signed a £7.3m influenza human challenge study (“Study”) contract with a leading biotechnology company to test its antiviral product using the hVIVO Influenza Human Challenge Study Model. The randomised, double-blinded, placebo-controlled study will test and assess the antiviral prophylactic and…

Open Orphan #ORPH – Trading Update, Volunteer Recruitment and Laboratory Facilities Expansion March 8, 2022 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, provides a trading update for the year ended 31 December 2021. The Company also announces it will be opening a new primary FluCamp volunteer recruitment screening facility in Plumbers Row, London (“Plumbers Row Facility”) and a secondary FluCamp recruitment facility in Manchester. Trading Update Subject to completion…

Open Orphan #ORPH – 2020 Annual Report and 2021 AGM Notice June 30, 2021 – Posted in: Blog, Open Orphan (ORPH)

Open Orphan plc (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organisation (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials, announces that the following documents have been sent to shareholders: · Annual Report and Accounts for the year ended 31 December 2020 (“2020 Annual Report”) · Notice of Annual General Meeting (“AGM”) 2021 and voting proxy form In accordance with AIM Rule 26, these documents are…

Open Orphan #ORPH – Exercise of Investor Warrants by Investors, Issue of Shares and TVR February 3, 2021 – Posted in: Open Orphan (ORPH)

Open Orphan (AIM: ORPH), a rapidly growing specialist pharmaceutical services clinical research organization (CRO) and a world leader in vaccine and antiviral testing using human challenge clinical trials , has received notice of exercise of warrants by investors who participated in the Venn loan note financing in December 2018 over 1,349,349 ordinary shares of 0.1 pence each in the capital of the Company (“Ordinary Shares”) at a price of 0.1 pence per share for 477,703 Ordinary Shares and…